

AMENDED ANNUAL REPORT

Fiscal Year – 2013

INFORMATION AND DISCLOSURE STATEMENT

Period Ending December 31, 2013



Medical Technologies

d/b/a

RIGHTSMILE, INC.

RIGHTSMILE, INC.
Amended Company Information and Disclosure Statement
For the Period Ending December 31, 2013

OTC Pink Basic Disclosure Guidelines

Item I: Name of the Issuer and its Predecessor(s):

From August, 2009 to Present:	Rightsmile, Inc.
From June 2007 to August 2009	Potential Holdings, Inc.
From June 2007 to July 2007	Axiom Management, Inc.
From May 2003 to June 2007	Green Power Energy Holdings Corp.
From Incorporation to May 2003	Dr. Owl Online, Inc.

Item II: The Address of the Issuer's Principal Executive Offices:

Company Headquarters:

11601 Wilshire Boulevard, Suite 500
Los Angeles, CA 90025
Tel. (855) 723-3283
www.BGMedTech.com
admin@bdmedtech.com

Investor Relations Contact:

None.

Item III: Security Information

Trading Symbol:	RIGH
Exact Title and Class of Securities Outs.:	Common Stock
CUSIP:	76657X 10 3
Total Shares Auth. As of 12/31/2013	30,000,000,000
Total Shares Issued as of 12/31/2013	29,999,999,468
Total Shares Outstanding as of 12/31/2013	29,999,999,468

Additional Class of Securities:

Trading Symbol:	None.
Exact Title and Class of Securities Outs.:	Series A Preferred Stock.
CUSIP:	None.
Total Shares Auth. As of 12/31/2013	5,000,000
Total Shares Issued as of 12/31/2013	3,565,000
Total Shares Outstanding as of 12/31/2013	3,565,000

Transfer Agent:

Standard Registrar & Transfer
12525 South 1840 East
Draper, UT 84020
Tel. 801.571.8844 Fax. 801.571.2551

List Any Restrictions on the Transfer of Security: None. Securities subject to applicable restrictions as provided in the Securities Act of 1933, and the rules promulgated thereunder, as amended.

Described any Trading Suspension Orders Issued by the SEC in the past 12 months: None.

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off or reorganization either currently anticipated or that occurred within the past 12 months: On September 20, 2013, the Issuer was re-domiciled in the State of Wyoming, such transaction constitutes an "Type F" reorganization under the Internal Revenue Code.

Item IV: Issuance History:

- (a) On or about November 25, 2013, the company issued 24,665,700,000 restricted shares of common stock, par value \$.00001, to Salvatore Tuzzolino as consideration for past and future services rendered to the company and cash receivables;
- (b) On or about November 25, 2013, the company issued Kelso Office Services, LLC, an Iowa limited liability company, 1,499,000,000 restricted shares of common stock, par value \$.00001, pursuant to Kelso's conversion of 149,000 shares of the company's Series A Preferred stock, at a conversion rate of 10,000 for 1;
- (c) On or about November 25, 2013, the company issued US Coproducts, LLC, an Iowa limited liability company, 1,499,000,000 restricted shares of common stock, par value \$.00001, pursuant to Coproduct's conversion of 149,000 shares of the company's Series A Preferred stock, at a conversion rate of 10,000 for 1;
- (d) On or about November 25, 2013, the company issued Salvatore Tuzzolino, 2,000,000 shares of common stock, par value \$.00001, pursuant to Mr. Tuzzolino's conversion of 2,000 shares of the company's Series A Preferred stock, at a conversion rate of 10,000 for 1; and
- (e) On or about December 6, 2013, the company issued 1,990,092,728 restricted shares of common stock, par value \$.00001, to Salvatore Tuzzolino as consideration for the forgiveness of certain amounts owed to Mr. Tuzzolino by the company;

Item V: Financial Statements.

The Issuer is filing the required financial statements for the period ending December 31, 2013 as a separate report through the OTC Disclosure & News Service. Those financial statements are incorporated by reference herein.

Item VI: Description of the Issuer's Business, Products and Services.

Description of the Issuer's Business Operations.

Rightsmile, Inc. d/b/a BG Medical Technologies, Inc. develops socially relevant technology systems and media content for the medical cannabis and alternative health industry that are the result of extensive analysis of scientific data collected through a proprietary network of software solutions, patients, and medical professionals.

The company's flagship product, BudGenius.com, launched in 2010 and is an informative website for medical cannabis patients, as well as a consumer safety service for dispensaries. BudGenius combines a medical cannabis testing laboratory with social Internet tools to help predict the therapeutic effects of thousands of marijuana strains by combining scientific data and crowd-sourced reviews. The platform is designed to assist patients in selecting cannabis medicine paired to their specific needs. BudGenius is recognized worldwide as a comprehensive online database for scientifically tested cannabis.

BG Medical Technologies operates its laboratory and executive center in Los Angeles, California. and its technology development centers in Los Angeles, California, and Ukraine.

Date and State of Incorporation.

The Issuer was organized under the laws of the State of Texas in February, 2001.

The Issuer was re-domiciled under the laws of the State of Delaware on March 28, 2003

The Issuer was re-domiciled under the laws of the State of Nevada on September 14, 2006

The Issuer was re-domiciled under the laws of the State of Wyoming on September 20, 2013

The Issuer's Primary and Secondary SIC Code.

Primary – 8700, Engineering, Research, Management

Secondary – 8999, Services not elsewhere classified

Principal Products or Services, and Their Markets

The Issuer offers medical cannabis testing and analysis for use by medical cannabis patients.

Item VII: Describe the Issuer's Facilities.

The Issuer leases its facilities at no cost pursuant to an unwritten agreement with the primary lessee of the premises.

Item VII: Officers, Directors and Control Persons.

Names of Officers, Directors and Control Persons:

<u>Name</u>	<u>Position</u>	<u>Business Address</u>
Angel Stanz	Chief Executive Officer	111601 Wilshire Blvd, #500, Los Angeles CA
Salvatore Tuzzolino	Control Shareholder	8502 E. Chapman Avenue, Orange CA

Legal/Disciplinary History:

(a) A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

N/A

(b) The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

N/A

(c) A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

N/A

(d) The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities.

N/A

Beneficial Owners:

Name	Position	Securities Owned
Angel Stanz	Chief Executive Officer	3,500,000 shares Series A Preferred
Salvatore Tuzzolino	Control Shareholder	26,655,792,728 shares common stock

Item IX: Service Providers.**Legal Counsel**

Adam S. Tracy
Securities Compliance Group, Ltd.
9107 Wilshire Blvd., Suite 450
Beverly Hills, CA 90210
Tel. (888) 978.9901
at@ibankattorneys.com

Accountant or Auditor

N/A

Investor Relations Contact

N/A

Other Advisor

N/A

ITEM X: Issuer Certification.

I, Aaron Stanz hereby certify that:

1. I have reviewed this Amended Annual Report for Fiscal Year 2013 of Rightsmile, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Dated: May 22, 2014

By: /s/ Aaron Stanz

Its: Chief Executive Officer